Transgene SA (TRGNF)
USD 0.7
(0.0%)
USD 0.7
(0.0%)
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2023 | 17.29 Million EUR | 606.21% |
| 2022 | 2.44 Million EUR | -36.29% |
| 2021 | 3.84 Million EUR | -27.24% |
| 2020 | 5.28 Million EUR | -68.3% |
| 2019 | 16.66 Million EUR | -57.14% |
| 2018 | 38.87 Million EUR | -7.82% |
| 2017 | 42.17 Million EUR | -6.78% |
| 2016 | 45.24 Million EUR | 24.25% |
| 2015 | 36.4 Million EUR | 0.56% |
| 2014 | 36.2 Million EUR | 2.53% |
| 2013 | 35.31 Million EUR | 26.89% |
| 2012 | 27.83 Million EUR | 33.21% |
| 2011 | 20.89 Million EUR | 0.0% |
| 2010 | - EUR | 0.0% |
| 2009 | - EUR | 0.0% |
| 2008 | - EUR | 0.0% |
| 2007 | - EUR | 0.0% |
| 2006 | - EUR | 0.0% |
| 2004 | 5.05 Million EUR | -8.7% |
| 2003 | 5.53 Million EUR | -5.98% |
| 2002 | 5.89 Million EUR | -5.73% |
| 2001 | 6.24 Million EUR | 0.5% |
| 2000 | 6.21 Million EUR | 8.42% |
| 1999 | 5.73 Million EUR | 40.3% |
| 1998 | 4.08 Million EUR | -5.4% |
| 1997 | 4.32 Million EUR | 0.0% |
| Year | Total Debt | Total Debt Growth |
|---|---|---|
| 2024 Q1 | 36.69 Million EUR | 112.16% |
| 2024 Q2 | 36.69 Million EUR | 0.25% |
| 2023 Q4 | 17.29 Million EUR | 7.72% |
| 2023 Q3 | 16.05 Million EUR | 772.55% |
| 2023 Q1 | 11.57 Million EUR | 372.44% |
| 2023 Q2 | 1.84 Million EUR | -84.1% |
| 2023 FY | 17.29 Million EUR | 606.21% |
| 2022 Q2 | 3.2 Million EUR | -78.97% |
| 2022 Q1 | 15.22 Million EUR | 295.99% |
| 2022 FY | 2.44 Million EUR | -36.29% |
| 2022 Q4 | 2.44 Million EUR | -80.13% |
| 2022 Q3 | 12.32 Million EUR | 285.1% |
| 2021 Q1 | 16.8 Million EUR | 218.08% |
| 2021 Q2 | 4.53 Million EUR | -73.02% |
| 2021 Q4 | 3.84 Million EUR | -74.97% |
| 2021 FY | 3.84 Million EUR | -27.24% |
| 2021 Q3 | 15.35 Million EUR | 238.74% |
| 2020 Q1 | 27.54 Million EUR | 65.32% |
| 2020 FY | 5.28 Million EUR | -68.3% |
| 2020 Q2 | 16.1 Million EUR | -41.56% |
| 2020 Q3 | 17.1 Million EUR | 6.22% |
| 2020 Q4 | 5.28 Million EUR | -69.11% |
| 2019 Q3 | 27.34 Million EUR | -5.22% |
| 2019 FY | 16.66 Million EUR | -57.14% |
| 2019 Q4 | 16.66 Million EUR | -39.07% |
| 2019 Q1 | 48.93 Million EUR | 25.87% |
| 2019 Q2 | 28.85 Million EUR | -41.03% |
| 2018 Q2 | 39.32 Million EUR | -32.89% |
| 2018 Q4 | 38.87 Million EUR | -33.32% |
| 2018 FY | 38.87 Million EUR | -7.82% |
| 2018 Q3 | 58.29 Million EUR | 48.23% |
| 2018 Q1 | 58.6 Million EUR | 38.96% |
| 2017 Q1 | 59.22 Million EUR | 30.91% |
| 2017 Q2 | 42.32 Million EUR | -28.53% |
| 2017 Q4 | 42.17 Million EUR | -30.75% |
| 2017 FY | 42.17 Million EUR | -6.78% |
| 2017 Q3 | 60.89 Million EUR | 43.87% |
| 2016 FY | 45.24 Million EUR | 24.25% |
| 2016 Q3 | 61.86 Million EUR | 36.21% |
| 2016 Q2 | 45.41 Million EUR | -26.77% |
| 2016 Q1 | 62.02 Million EUR | 70.35% |
| 2016 Q4 | 45.24 Million EUR | -26.87% |
| 2015 Q3 | 52.64 Million EUR | 18.23% |
| 2015 FY | 36.4 Million EUR | 0.56% |
| 2015 Q1 | 59.57 Million EUR | 64.55% |
| 2015 Q2 | 44.52 Million EUR | -25.27% |
| 2015 Q4 | 36.4 Million EUR | -30.84% |
| 2014 Q4 | 36.2 Million EUR | -29.13% |
| 2014 FY | 36.2 Million EUR | 2.53% |
| 2014 Q2 | 43.91 Million EUR | -24.74% |
| 2014 Q1 | 58.34 Million EUR | 65.22% |
| 2014 Q3 | 51.09 Million EUR | 16.35% |
| 2013 FY | 35.31 Million EUR | 26.89% |
| 2013 Q2 | 35.77 Million EUR | -22.18% |
| 2013 Q4 | 35.31 Million EUR | -27.42% |
| 2013 Q3 | 48.65 Million EUR | 36.01% |
| 2013 Q1 | 45.97 Million EUR | 65.17% |
| 2012 Q2 | - EUR | 0.0% |
| 2012 Q4 | 27.83 Million EUR | 0.0% |
| 2012 FY | 27.83 Million EUR | 33.21% |
| 2011 FY | 20.89 Million EUR | 0.0% |
| 2011 Q4 | 20.89 Million EUR | 0.0% |
| 2011 Q2 | - EUR | 0.0% |
| 2010 Q2 | - EUR | 0.0% |
| 2010 FY | - EUR | 0.0% |
| 2010 Q4 | - EUR | 0.0% |
| 2009 Q4 | - EUR | 0.0% |
| 2009 FY | - EUR | 0.0% |
| 2009 Q2 | - EUR | 0.0% |
| 2008 FY | - EUR | 0.0% |
| 2008 Q4 | - EUR | 0.0% |
| 2007 FY | - EUR | 0.0% |
| 2006 FY | - EUR | 0.0% |
| 2005 Q2 | - EUR | 0.0% |
| 2004 Q4 | 5.05 Million EUR | 0.0% |
| 2004 Q2 | - EUR | 0.0% |
| 2004 Q1 | - EUR | -100.0% |
| 2004 FY | 5.05 Million EUR | -8.7% |
| 2003 FY | 5.53 Million EUR | -5.98% |
| 2003 Q3 | - EUR | 0.0% |
| 2003 Q4 | 5.53 Million EUR | 0.0% |
| 2003 Q1 | - EUR | -100.0% |
| 2003 Q2 | - EUR | 0.0% |
| 2002 FY | 5.89 Million EUR | -5.73% |
| 2002 Q4 | 5.89 Million EUR | 0.0% |
| 2002 Q1 | - EUR | -100.0% |
| 2002 Q3 | - EUR | 0.0% |
| 2002 Q2 | - EUR | 0.0% |
| 2001 Q3 | - EUR | 0.0% |
| 2001 Q2 | - EUR | 0.0% |
| 2001 FY | 6.24 Million EUR | 0.5% |
| 2001 Q4 | 6.24 Million EUR | 0.0% |
| 2001 Q1 | - EUR | -100.0% |
| 2000 Q4 | 6.21 Million EUR | 0.0% |
| 2000 Q1 | - EUR | -100.0% |
| 2000 Q2 | - EUR | 0.0% |
| 2000 Q3 | - EUR | 0.0% |
| 2000 FY | 6.21 Million EUR | 8.42% |
| 1999 FY | 5.73 Million EUR | 40.3% |
| 1999 Q4 | 5.73 Million EUR | 0.0% |
| 1998 Q4 | 4.08 Million EUR | 0.0% |
| 1998 FY | 4.08 Million EUR | -5.4% |
| 1997 FY | 4.32 Million EUR | 0.0% |
| Name | Total Debt | Total Debt Difference |
|---|---|---|
| Burzynski Research Institute, Inc. | - USD | -Infinity% |
| Santhera Pharmaceuticals Holding AG | 29.76 Million USD | 41.899% |
| Neon Bloom, Inc. | 630.07 Thousand USD | -2644.903% |
| Nascent Biotech, Inc. | 122.5 Thousand USD | -14018.367% |
| Qrons Inc. | 351.84 Thousand USD | -4815.489% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -2187.081% |
| Evofem Biosciences, Inc. | 43.37 Million USD | 60.125% |
| BioStem Technologies, Inc. | 4.71 Million USD | -267.087% |
| Skye Bioscience, Inc. | 4.61 Million USD | -274.735% |
| ProtoKinetix, Incorporated | - USD | -Infinity% |
| Rebus Holdings, Inc. | 310 Thousand USD | -5479.032% |
| CSL Limited | 12.18 Billion USD | 99.858% |
| Northwest Biotherapeutics, Inc. | 45.56 Million USD | 62.039% |
| Capstone Therapeutics Corp. | 20.32 Million USD | 14.92% |
| Acro Biomedical Co., Ltd. | 25.71 Thousand USD | -67146.005% |
| Adynxx, Inc. | - USD | -Infinity% |
| Arch Therapeutics, Inc. | 5.87 Million USD | -194.579% |
| Eiger BioPharmaceuticals, Inc. | 41.2 Million USD | 58.025% |
| Nanobac Pharmaceuticals, Incorporated | 4.12 Million USD | -319.582% |
| Institute of Biomedical Research Corp. | 401.84 Thousand USD | -4203.855% |
| SQZ Biotechnologies Company | 27.47 Million USD | 37.043% |
| Intellipharmaceutics International Inc. | 2.32 Million USD | -643.566% |
| Propanc Biopharma, Inc. | 948.27 Thousand USD | -1723.846% |
| Mesoblast Limited | 118.7 Million USD | 85.43% |
| Marizyme, Inc. | 18.71 Million USD | 7.6% |
| Genus plc | 233.1 Million USD | 92.58% |
| VioQuest Pharmaceuticals, Inc. | 2.93 Million USD | -490.195% |
| Pharming Group N.V. | 171.54 Million USD | 89.918% |
| Therapeutic Solutions International, Inc. | 888.06 Thousand USD | -1847.495% |
| CNBX Pharmaceuticals Inc. | 1.34 Million USD | -1187.229% |
| Nymox Pharmaceutical Corporation | 750 Thousand USD | -2206.0% |
| ContraFect Corporation | 2.88 Million USD | -500.312% |
| PsyBio Therapeutics Corp. | 135.48 Thousand USD | -12665.062% |
| Sienna Biopharmaceuticals, Inc. | - USD | -Infinity% |
| RegeneRx Biopharmaceuticals, Inc. | 1.44 Million USD | -1095.794% |
| IMV Inc. | 28.88 Million USD | 40.122% |
| AXIM Biotechnologies, Inc. | 5.65 Million USD | -205.654% |
| MultiCell Technologies, Inc. | 202.58 USD | -8537267.953% |
| ONE Bio Corp. | 19.71 Million USD | 12.275% |
| Accustem Sciences Inc. | - USD | -Infinity% |
| RVL Pharmaceuticals plc | 57.48 Million USD | 69.916% |
| Arno Therapeutics, Inc. | - USD | -Infinity% |
| EV Biologics, Inc. | 1.49 Million USD | -1057.049% |
| Q BioMed Inc. | 4.1 Million USD | -320.805% |
| Emmaus Life Sciences, Inc. | 33.1 Million USD | 47.751% |
| Mosaic ImmunoEngineering Inc. | 1.22 Million USD | -1307.974% |
| Biomind Labs Inc. | 735.54 Thousand USD | -2251.327% |
| American Oriental Bioengineering, Inc. | 67.64 Million USD | 74.432% |
| Provectus Biopharmaceuticals, Inc. | 3.02 Million USD | -471.511% |
| TetraLogic Pharmaceuticals Corporation | - USD | -Infinity% |
| Oncotelic Therapeutics, Inc. | 12.99 Million USD | -33.069% |
| GlobeStar Therapeutics Corporation | 359.71 Thousand USD | -4708.04% |
| THC Farmaceuticals, Inc. | 141.51 Thousand USD | -12121.06% |
| Curative Biotechnology, Inc. | 2.25 Million USD | -665.814% |
| GB Sciences, Inc. | 1.75 Million USD | -883.058% |
| Alpha Cognition Inc. | 1.22 Million USD | -1317.191% |
| HST Global, Inc. | 98.31 Thousand USD | -17490.7% |
| Wesana Health Holdings Inc. | 248.72 Thousand USD | -6853.602% |
| Halberd Corporation | 150 Thousand USD | -11430.0% |
| Enzolytics Inc. | 996.33 Thousand USD | -1635.857% |
| Agentix Corp. | 50 Thousand USD | -34490.0% |
| Resverlogix Corp. | 6.49 Million USD | -166.446% |
| Nuo Therapeutics, Inc. | 255.59 Thousand USD | -6666.644% |
| MetaStat, Inc. | - USD | -Infinity% |
| argenx SE | 20 Million USD | 13.525% |
| Enzon Pharmaceuticals, Inc. | - USD | -Infinity% |
| Endonovo Therapeutics, Inc. | 7.07 Million USD | -144.528% |
| RespireRx Pharmaceuticals Inc. | 2.7 Million USD | -538.497% |
| GeneThera, Inc. | - USD | -Infinity% |
| Inhibitor Therapeutics, Inc. | - USD | -Infinity% |
| AVAX Technologies, Inc. | - USD | -Infinity% |
| Zenith Capital Corp. | 10.22 Thousand USD | -169044.254% |
| Genscript Biotech Corporation | 417.73 Million USD | 95.86% |
| Ember Therapeutics, Inc. | 200.61 Thousand USD | -8520.947% |
| Anthera Pharmaceuticals, Inc. | - USD | -Infinity% |
| Sigyn Therapeutics, Inc. | 2.39 Million USD | -621.309% |
| WPD Pharmaceuticals Inc. | 229.29 Thousand USD | -7442.817% |
| Cotinga Pharmaceuticals Inc. | 148.65 Thousand USD | -11534.399% |
| Kadimastem Ltd | 891.22 Thousand USD | -1840.585% |
| Helix BioMedix, Inc. | - USD | -Infinity% |
| VitaSpring Biomedical Co. Ltd. | - USD | -Infinity% |
| Oncology Pharma Inc. | - USD | -Infinity% |
| Reve Technologies, Inc. | 250.18 Thousand USD | -6812.967% |
| LadRx Corporation | 33.6 Thousand USD | -51364.024% |
| Cell Source, Inc. | 9.25 Million USD | -86.889% |
| Regen BioPharma, Inc. | 756.2 Thousand USD | -2187.081% |
| NovAccess Global Inc. | 2.19 Million USD | -686.179% |
| Affymax, Inc. | - USD | -Infinity% |
| Itoco Inc. | 228.37 Thousand USD | -7473.004% |
| Rasna Therapeutics, Inc. | 210.97 Thousand USD | -8097.654% |
| Pathfinder Cell Therapy, Inc. | 4.98 Million USD | -247.08% |
| Mobile Lads Corp. | 484.28 Thousand USD | -3471.252% |
| CytoDyn Inc. | 30.07 Million USD | 42.496% |
| Claritas Pharmaceuticals, Inc. | - USD | -Infinity% |
| NDT Pharmaceuticals Inc. | - USD | -Infinity% |
| NanoSphere Health Sciences Inc. | - USD | -Infinity% |
| Alseres Pharmaceuticals, Inc. | 7.81 Million USD | -121.165% |
| SYBLEU INC | 477.5 Thousand USD | -3521.99% |
| Advanced Proteome Therapeutics Corporation | - USD | -Infinity% |
| ImmunoCellular Therapeutics, Ltd. | 4.73 Million USD | -265.237% |
| International Stem Cell Corporation | 4.17 Million USD | -313.954% |
| Bioxytran, Inc. | 1.92 Million USD | -798.442% |
| GlobeImmune, Inc. | - USD | -Infinity% |
| Predictive Technology Group, Inc. | - USD | -Infinity% |
| ProText Mobility, Inc. | 62.41 Thousand USD | -27610.573% |
| Cardax, Inc. | - USD | -Infinity% |
| VG Life Sciences Inc. | 2.18 Million USD | -693.021% |
| Kaleido Biosciences, Inc. | - USD | -Infinity% |
| Advaxis, Inc. | 8.31 Million USD | -107.973% |
| Adhera Therapeutics, Inc. | 8.58 Million USD | -101.456% |
| RenovaCare, Inc. | - USD | -Infinity% |
| Regnum Corp. | 1.55 Million USD | -1011.876% |
| Innovation Pharmaceuticals Inc. | 268 Thousand USD | -6353.358% |
| Neutra Corp. | 54.15 Thousand USD | -31835.52% |
| Windtree Therapeutics, Inc. | 1.83 Million USD | -845.082% |
| PureTech Health plc | 25.51 Million USD | 32.208% |
| Coeptis Therapeutics, Inc. | 1.22 Million USD | -1312.729% |
| IXICO plc | 472.02 Thousand USD | -3564.016% |
| IntelGenx Technologies Corp. | 15.5 Million USD | -11.573% |
| Gelesis Holdings, Inc. | 62.26 Million USD | 72.223% |
| CSL Limited | 12.18 Billion USD | 99.858% |
| Cellectis S.A. | 92.77 Million USD | 81.358% |